SCHEMBL5407957

SCHEMBL5407957

CCCCC(=O)Nn1cnc2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.63
ALOX15 P16050 1/20 0.61
HSD17B10 Q99714 1/20 0.61
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C19 P33261 1/20 0.60
ASAH1 Q13510 1/20 0.52
KDM4E B2RXH2 3/20 0.46
NPC1 O15118 1/20 0.46
EGLN3 Q9H6Z9 1/20 0.44
HPGD P15428 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18991593 0.87 HSD17B10 (0.66) LMNAALOX15HSD17B10CYP1A2CYP3A4
SCHEMBL6234447 0.82 ALOX15 (0.64) LMNAALOX15HSD17B10CYP1A2CYP3A4
SCHEMBL6954737 0.79 ALOX15 (0.58) ALOX15HSD17B10CYP1A2CYP3A4CYP2D6
SCHEMBL1685055 0.77 HSD17B10 (0.61) ALOX15HSD17B10CYP1A2CYP3A4CYP2D6
SCHEMBL8419574 0.77 CYP1A2 (0.60) LMNAALOX15HSD17B10CYP1A2CYP3A4
SCHEMBL204727 0.77 ALOX15 (0.64) LMNAALOX15HSD17B10CYP1A2CYP3A4
SCHEMBL27823707 0.75 ALOX15 (0.52) LMNAALOX15HSD17B10CYP1A2CYP3A4
SCHEMBL707209 0.75 ALOX15 (0.58) LMNAALOX15HSD17B10CYP1A2CYP3A4
SCHEMBL7105937 0.75 ASAH1 (0.56) LMNAALOX15HSD17B10CYP1A2CYP3A4
SCHEMBL11845978 0.74 ALOX15 (0.53) ALOX15HSD17B10CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
EP-1675844-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE Sterix Limited (GB) 2006-07-05 EP disclosed
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2005-10-13 US disclosed
WO-2005042513-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE STERIX LIMITED (GB) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors HSD3B1, HSD3B2, HSD17B3 LMNA 646/4885ALOX15 745/4885HSD17B10 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.